EAN guideline on palliative care of people with severe, progressive multiple sclerosis.
GRADE assessment
clinical practice guideline
multiple sclerosis
palliative care
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
03
03
2020
accepted:
25
03
2020
pubmed:
30
5
2020
medline:
24
6
2021
entrez:
30
5
2020
Statut:
ppublish
Résumé
Patients with severe, progressive multiple sclerosis (MS) have complex physical and psychosocial needs, typically over several years. Few treatment options are available to prevent or delay further clinical worsening in this population. The objective was to develop an evidence-based clinical practice guideline for the palliative care of patients with severe, progressive MS. This guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation methodology. Formulation of the clinical questions was performed in the Patients-Intervention-Comparator-Outcome format, involving patients, carers and healthcare professionals (HPs). No uniform definition of severe MS exists: in this guideline, constant bilateral support required to walk 20 m without resting (Expanded Disability Status Scale score > 6.0) or higher disability is referred to. When evidence was lacking for this population, recommendations were formulated using indirect evidence or good practice statements were devised. Ten clinical questions were formulated. They encompassed general and specialist palliative care, advance care planning, discussing with HPs the patient's wish to hasten death, symptom management, multidisciplinary rehabilitation, interventions for caregivers and interventions for HPs. A total of 34 recommendations (33 weak, 1 strong) and seven good practice statements were devised. The provision of home-based palliative care (either general or specialist) is recommended with weak strength for patients with severe, progressive MS. Further research on the integration of palliative care and MS care is needed. Areas that currently lack evidence of efficacy in this population include advance care planning, the management of symptoms such as fatigue and mood problems, and interventions for caregivers and HPs.
Sections du résumé
BACKGROUND AND PURPOSE
Patients with severe, progressive multiple sclerosis (MS) have complex physical and psychosocial needs, typically over several years. Few treatment options are available to prevent or delay further clinical worsening in this population. The objective was to develop an evidence-based clinical practice guideline for the palliative care of patients with severe, progressive MS.
METHODS
This guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation methodology. Formulation of the clinical questions was performed in the Patients-Intervention-Comparator-Outcome format, involving patients, carers and healthcare professionals (HPs). No uniform definition of severe MS exists: in this guideline, constant bilateral support required to walk 20 m without resting (Expanded Disability Status Scale score > 6.0) or higher disability is referred to. When evidence was lacking for this population, recommendations were formulated using indirect evidence or good practice statements were devised.
RESULTS
Ten clinical questions were formulated. They encompassed general and specialist palliative care, advance care planning, discussing with HPs the patient's wish to hasten death, symptom management, multidisciplinary rehabilitation, interventions for caregivers and interventions for HPs. A total of 34 recommendations (33 weak, 1 strong) and seven good practice statements were devised.
CONCLUSIONS
The provision of home-based palliative care (either general or specialist) is recommended with weak strength for patients with severe, progressive MS. Further research on the integration of palliative care and MS care is needed. Areas that currently lack evidence of efficacy in this population include advance care planning, the management of symptoms such as fatigue and mood problems, and interventions for caregivers and HPs.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1510-1529Subventions
Organisme : Fondazione Italiana Sclerosi Multipla
ID : 2017/S/2
Pays : International
Organisme : European Academy of Neurology
Pays : International
Informations de copyright
© 2020 European Academy of Neurology and European Association of Palliative Care.
Références
Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers 2018; 4: 43.
Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 67-75.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
Fraser R, Ehde D, Amtmann D, et al. Self-management for people with multiple sclerosis: report from the first international consensus conference. Int J MS Care 2013; 15: 99-106.
Hirst C, Swingler R, Compston DA, et al. Survival and causes of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry 2008; 79: 1016-1021.
Sumelahti ML, Hakama M, Elovaara I, et al. Causes of death among patients with multiple sclerosis. Mult Scler 2010; 16: 1437-1442.
Lunde HMB, Assmus J, Myhr KM, Bo L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry 2017; 88: 621-625.
Campbell CW, Jones EJS, Merrills J. Palliative and end-of-life care in advanced Parkinson's disease and multiple sclerosis. J Clin Med 2010; 10: 290-292.
Sleeman KE, Ho YK, Verne J, et al. Place of death, and its relation with underlying cause of death, in Parkinson's disease, motor neuron disease, and multiple sclerosis: a population-based study. Palliat Med 2013; 27(9): 840-846.
Oliver DJ, Borasio GD, Caraceni A, et al. A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol 2016; 23: 30-38.
Strupp J, Ehmann C, Galushko M, et al. Risk factors for suicidal ideation in patients feeling severely affected by multiple sclerosis. J Palliat Med 2016; 19(5): 523-528.
de Groot V. There is an urgent need for palliative care specialists in MS - commentary. Mult Scler 2019; 25(13): 1713-1714.
Köpke S, Giordano A, Veronese S, et al. Patient and caregiver involvement in formulation of guideline questions: findings from the EAN guideline on palliative care of people with severe multiple sclerosis. Eur J Neurol 2019; 26(1): 41-50.
Leone MA, Keindl M, Schapira AH, Deuschl G, Federico A. Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces. Eur J Neurol 2015; 22: 1505-1510.
Guyatt GH, Oxman AD, Kunz R, et al. guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011; 64: 395-400.
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 ed. Chichester: The Cochrane Collaboration and John Wiley & Sons Ltd, 2011: 187-242.
Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010; 340: c221.
Edmonds P, Hart S, Gao Wei, et al. Palliative care for people severely affected by multiple sclerosis: evaluation of a novel palliative care service. Omega J Death Dying 2010; 16: 627-636.
Veronese S, Gallo G, Valle A, et al. Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study. BMJ Support Palliat Care 2017; 7: 164-172.
Solari A, Giordano A, Patti F, et al. Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. Mult Scler 2018; 24: 663-674.
Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 2017; 36: 855-875.
Donders AR, van der Heijden GJ, Stijnen T, et al. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087-1091.
Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32: 451-459.
Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-1131.
Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler 2012; 18: 219-228.
Hsu CC, Sanford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval 2007; 12: 1-8.
Sepulveda C, Marlin A, Yoshida T, et al. Palliative care: the World Health Organization’s global perspective. J Pain Symptom Manage 2002; 24: 91-96.
Radbruch L, Payne S. White paper on standards and norms for hospice and palliative care in Europe: Part 1. Eur J Palliat Care 2009; 16(6): 278-289.
Embrey N. Exploring the lived experience of palliative care for people with MS, 2: Therapeutic interventions. Br J Neurosci Nurs 2009; 5(7): 311-318.
Embrey N. Exploring the lived experience of palliative care for people with MS, 3: Views of group support. Br J Neurosci Nurs 2009; 5(9): 402-408.
Borreani C, Bianchi E, Pietrolongo E, et al. Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. PLoS One 2014; 9(10): e109679.
Higginson IJ, Hart S, Burman R, et al. Randomised controlled trial of a new palliative care service: compliance, recruitment and completeness of follow-up. BMC Palliat Care 2008; 7: 7.
Higginson IJ, McCrone P, Hart SR, et al. Is short-term palliative care cost-effective in multiple sclerosis? A randomized phase II trial. J Pain Symptom Manage 2009; 38: 816-826.
Solari A, Giordano A, Grasso MG, et al. Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. Trials 2015; 16: 184.
Giovannetti AM, Borreani C, Bianchi E, et al. Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: a qualitative study. PLoS One 2018; 13(7): e0200532.
Rietjens JAC, Sudore RL, Connolly M, et al. Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care. Lancet Oncol 2017; 18(9): e543-e551.
Brinkman-Stoppelenburg A, Rietjens JAC, van der Heide A. The effects of advance care planning on end-of-life care: a systematic review. Palliat Med 2014; 28(8): 1000-1025.
Golla H, Mammeas S, Galushko M, et al. Unmet needs of caregivers of severely affected multiple sclerosis patients: a qualitative study. Palliat Support Care 2015; 13(6): 1685-1693.
Golla H, Galushko M, Strupp J, et al. Patients feeling severely affected by multiple sclerosis: addressing death and dying. Omega J Death Dying 2016; 74(2): 275-291.
Walter HAW, Seeber AA, Willems DL, de Visser M. The role of palliative care in chronic progressive neurological diseases - a survey amongst neurologists in the Netherlands. Front Neurol 2019; 14(9): 1157.
Chen H, Habermann B. Ready or not: planning for health declines in couples with advanced multiple sclerosis. J Neurosci Nurs 2013; 45: 38-43.
McCurry MK. An exploratory study of decision making by informal caregivers of individuals with multiple sclerosis. J Neurosci Nurs 2013; 45(1): 52-60.
Berkman CS, Cavallo PF, Chesnut WC, Holland NJ. Attitudes toward physician-assisted suicide among persons with multiple sclerosis. J Palliat Med 1999; 2(1): 51-63.
Strupp J, Voltz R, Golla H. Opening locked doors: integrating a palliative care approach into the management of patients with severe multiple sclerosis. Mult Scler 2016; 22: 13-18.
Marrie RA, Salter A, Tyry T, et al. High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology 2017; 88(16): 1528-1534.
Hall L. Factors that predict desire for hastened death in individuals with multiple sclerosis. Diss Abstr Int 2005; 66(4-B): 2307.
Radbruch L, Leget C, Bahr P, et al. Euthanasia and physician-assisted suicide: a white paper from the European Association for Palliative Care. Palliat Med 2016; 30(2): 104-116.
Heine M, van de Port I, Rietberg MB, van Wegen EE, Kwakkel G. Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2015; (9): CD009956. https://doi.org/10.1002/14651858.CD009956.pub2.
NICE. Multiple Sclerosis in Adults: Management (CG186). London: NICE, 2014.
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 2010(17): 1113-1123.
NICE. Neuropathic Pain in Adults: Pharmacological Management in Non-Specialist Settings (CG173). London: NICE, 2013.
Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol 2019; 26(6): 831-849.
Phé V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 2016; 13: 276-288.
NICE. Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease (CG148). London: NICE, 2012.
Wade DT. Measurement in Neurological Rehabilitation. Oxford: Oxford University Press, 1992.
Khan F, Turner-Stokes L, Ng L, Kilpatrick T. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev 2007; 2: CD006036.
World Health Organisation (WHO). International Classification of Functioning, Disability and Health (ICF). Geneva: WHO, 2001.
Guagenti-Tax EM, DiLorenzo TA, Tenteromano L, et al. Impact of a comprehensive long-term care program on caregiver and person with multiple sclerosis. Int J MS Care 2000; 2: 5-18.
Turner-Stokes L, Sykes N, Silber E, Khatri A, Sutton L, Young E. From diagnosis to death: exploring the interface between neurology, rehabilitation and palliative care in managing people with long-term neurological conditions. Clin Medicine 2007; 7: 129-36.
Dallara A, Tolchin DW. Emerging subspecialties in neurology: palliative care. Neurology 2014; 82(7): 640-642.
Robinson MT, Barrett KM. Emerging subspecialties in neurology: neuropalliative care. Neurology 2014; 82(21): e180-e182.
Boersma I, Miyasaki J, Kutner J, Kluger B. Palliative care and neurology: time for a paradigm shift. Neurology 2014; 83(6): 561-567.
Creutzfeldt CJ, Gooley T, Walker M. Are neurology residents prepared to deal with dying patients? Arch Neurol 2009; 66: 1427-1428.
Latorraca CO, Martimbianco ALC, Pachito DV, et al. Palliative care interventions for people with multiple sclerosis. Cochrane Database Syst Rev 2019; 10: CD012936.
Freeman J, Hendrie W, Jarrett L, et al. Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis. Lancet Neurol 2019; 18: 736-747.
van der Steen JT, Radbruch L, Hertogh CMPM, et al. White paper defining optimal palliative care in older people with dementia: a Delphi study and recommendations from the European Association for Palliative Care. Palliat Med 2014; 28(3): 197-209.
Curtis JR, Downey L, Back AL, et al. Effect of a patient and clinician communication-priming intervention on patient-reported goals-of-care discussions between patients with serious illness and clinicians: a randomized clinical trial. JAMA Intern Med 2018; 178(7): 930-940.